Effect of Enhanced External Counterpulsation

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2024

Conditions
Enhanced External Counterpulsation (EECP)Acute Myocardial Infarction (AMI)Drug-coated BalloonCardiac Rehabilitation
Interventions
OTHER

conventional drug and exercise rehabilitation

patients in the control group received antiplatelet agents (100 mg of aspirin and 75 mg of clopidogrel, once a day), β-blocker (25-100 mg of metoprolol, twice a day, with the dose adjusted based on the patient's heart rate) and statins (10-20 mg of rosuvastatin, every night). In addition, the patients received exercise rehabilitation (e.g. aerobic, resistance and flexibility training) for 30-60 min, 3-5 times/week.

DEVICE

EECP-based rehabilitation regimen

Patients in the rehabilitation group received the same medication and exercise rehabilitation as the control group during the trial period after undergoing DCB-based PCI DCBs; in addition, they were provided with EECP treatment after 7 days of medication. The treatment adopted a P-ECP/TI EECP device with a pressure setting of 0.020-0.035 MPa. Based on patients' actual tolerance, the treatment pressure and inflation and exhaust times were adjusted to a diastolic/systolic blood pressure ratio of \>1.2 and a diastolic/systolic pressure area of 1.5-2.0. The treatment was applied daily for 1 hour, 6 days a week, for a total of 36 hours.

Trial Locations (1)

Unknown

P-ECP/TI EECP device, Shanghai

All Listed Sponsors
lead

Chongming Hospital Affiliated to Shanghai University of Health & Medicine Sciences

OTHER

NCT06877390 - Effect of Enhanced External Counterpulsation | Biotech Hunter | Biotech Hunter